Clinical Trials

A Phase 3 clinical trial is currently recruiting to evaluate adjunctive pharmacotherapy targeting homovanillic acid and central dopaminergic pathways for major psychiatric mood disorders, specifically depression and anhedonia. Sponsored by academic and regional healthcare institutions, including Lund University and Region Skane, the active study assesses targeted interventions to modulate catecholaminergic signaling. Consequently, clinical research on this pathway remains focused on late-stage evaluations for major depressive disorders and related neurochemical deficits.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05355337 Recruiting
Psychiatric Disorders Mood|Anhedonia|Depression
Region Skane|Lund University
 2023-02-08 Phase 3

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Homovanillic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Homovanillic acid functions as a key dopamine metabolite that participates in catecholamine catabolism and serves as a substrate indicator for oxidative enzymatic activity within central neural pathways. Regulation of this metabolic pathway modulates synaptic dopaminergic signaling and cellular oxidation, which is directly relevant to therapeutic interventions evaluated for psychiatric mood disorders, including depression and anhedonia.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.